Find your path to Volker
394 people in our graph share verified history with Volker — schools, employers, funds. One of them is your warm intro.
Lars PedersenunlockedVolker: together at Yale School of Medicine (2000)
×4Volker: together at University of Cologne
×4Volker: together at Yale School of Medicine
×3Volker: together at AstraZeneca
Executive Vice President of Research & Development at Noema Pharma
Intro paths
→
In turn, Volker can intro founders to Noema Pharma's investors below.
Noema Pharma's investors · 9
BioMedPartnersBasel · $648K – $6.5M checksEQTNew York · since 2025EQT Life SciencesLuxembourg · $11M – $66M checks · since 2025ForbionNaarden · since 2025Gilde HealthcareUtrecht · $1.1M – $55M checks · since 2025InvusNew York · since 2025Jeito CapitalParis · since 2025Roche Venture FundBasel · $648K – $3.2M checksSofinnova PartnersParis · $540K – $27M checks · since 2025
Experience
- Noema PharmaEVP, Research and Developmentcurrent2024 — presentUnited States
- Sutura Therapeutics LtdMember Board Of Directors2021 — 2024Alderley Edge, England, United Kingdom
- Aurinia Pharmaceuticals Inc.Executive Vice President, Research and Development2022 — 2024Rockville, MD
- GW Pharmaceuticals plcEVP R&D, CMO2017 — 2021San Diego, CA
- Teva PharmaceuticalsVP, Head, Global Clinical Development, Multiple Sclerosis and Biosimilars2012 — 2017Greater Philadelphia Area
- MedImmuneClinical Development CNS2011 — 2012Gaithersburg, Maryland, United States
- Bayer HealthCare Manufacturing S.r.l.Clinical Development and Medical Affairs2002 — 2012United States
- AstraZenecaCNS Drug Development2000 — 2002Greater Philadelphia
- Yale University School of MedicineChief Resident1996 — 2000New Haven CT
Skills & more
CMO managementExecutive TeamStrategic PlanningPain ManagementHEORGlobal StrategyCNS disordersResearch and Development (R&D)Chief Medical OfficerNew Drug Application (NDA)PharmaceuticalsBoard of Directors Reporting
+12 more
Knowledge AcquisitionBoard of DirectorsRegenerative MedicineClear VisionProcesses DevelopmentBudgetingTherapeuticsStrategic LeadershipNeurologyClinical DevelopmentClinical TrialsMedical AffairsLanguages English · German · Latin · Spanish
- Medical Practitioner — State of Connecticut
- Medical Practitioner — State of New Jersey
From Volker's professional profile.
Frequently asked questions
- Who is Volker Knappertz?
- Executive Vice President of Research & Development at Noema Pharma
- Where does Volker Knappertz work?
- Volker Knappertz is Executive Vice President of Research & Development at Noema Pharma.
- Where did Volker Knappertz go to school?
- Volker Knappertz studied at Yale School of Medicine (MD, Neurology Residency); Wake Forest University School of Medicine (Neuroimaging and Stroke Fellowship., Fellow Cerebrovascular Disease and Neuroimaging); University of Cologne (Doctor of Medical Science, Medicine).
Same school
Also attended Yale School of Medicine73
Lars PedersenPartner, Chief Financial Officer at Redpoint VenturesAlexi Nazem, MDGeneral Partner at AlleyCorpElias QuijanoPrincipal at Northpond VenturesJeffrey LowPartner at Averin CapitalBridget Martell MA, MDSenior Biopharmaceutical Advisor at Two Bear CapitalAlley (Welsh) OlshanskyAdvisor at Casdin Capital
+ 67 more
Also attended Wake Forest University School of Medicine16
Paulina HillPartner at Sanofi VenturesDavid AdairCo-Founder and Managing Director at Solas BioVenturesMark G. CurrieVenture Partner at Iaso VenturesSamantha PulliamCEO and Chief Medical Officer at Axena HealthRobert GlanzmanExecutive Officer at CleneCHRISTOPHER TOOMBSExecutive Officer at Proniras
+ 10 more
Also attended University of Cologne119
Andrea GazviniAssociate at NorthzoneJohann FriederichAssociate at Notion CapitalPatrick MeisbergerManaging Partner at CommerzVenturesAlex PortoInvestor at Riverwood CapitalNicolas El BazeSenior Advisor at Partech VenturesMarkus MerzInvestment Manager at Capnamic
+ 113 more
Also attended University of Düsseldorf33
Ruslan BekbulatovInvestment Principal at Robert Bosch Venture CapitalMatthias LaisManaging Director at neosfer GmbHTheodor SchultePrincipal at EnBW New Ventures GmbHKlaus BreinerManaging Partner at Pureos BioventuresIsabella FandrychGeneral Partner at Nucleus CapitalAntje Hensel-RothChief People and External Affairs Officer at Intermediate Capital Group
+ 27 more
Shared employers
Also worked at GW Pharmaceuticals plc4
Also worked at Teva Pharmaceuticals52
Catherine Pearce, DHSc, MBAAdvisor at CincyTechElad BaronInvestment Professional at Key1 CapitalElaine ShannonPresident, Global Supply & Quality at Takeda VenturesRiki MozesVice President, Chief People Officer at Jerusalem Venture Partners (JVP)Jill DeSimoneDigital Pharma Advisor at Excelerate Health VenturesPerry NisenExecutive Advisor, Private Equity at Sofinnova Ventures
+ 46 more
Also worked at AstraZeneca159
Detlev BiniszkiewiczManaging Director at MPM BioImpactBriggs MorrisonEntrepreneur Partner at MPM BioImpactJung Lee, PhDVenture Partner at Adelphi Ventures Management, LlcJohan LundVenture Partner at ScietyIliam BarkinoInvestor at IndustrifondenSara JawadInvestor at Industrifonden
+ 153 more
Also worked at Yale University School of Medicine80
Karthik ArdhanareeswaranInvestor at GV (Google Ventures)Brittany de KouchkovskyDirector, University Relations at Osage University PartnersDavid Rosenthal, MDVenture Partner at AlleyCorpAlley (Welsh) OlshanskyAdvisor at Casdin CapitalSophie RobinsonSenior Associate at Cure VenturesMichael RechtChair, P2C Scientific Advisory Group and Chief Medical and Scientific Advisor at Pathway to Cures
+ 74 more